ABT Stock Analysis: Abbott Laboratories | NYSE
Medical Devices | NYSE, USA | Market Cap: 167.311m USD | 12M Return: -25% | US0028241000 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 864M
EPS Trend: 98.7%
Qual. Beats: 1
Rev. Trend: 98.4%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Abbott Laboratories (NYSE: ABT) is a diversified global healthcare company that discovers, develops, manufactures, and sells health care products across four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for conditions ranging from pancreatic exocrine insufficiency and irritable bowel syndrome to hypertension and migraine, alongside anti-infective and influenza vaccine products. Its diagnostics portfolio spans immunoassay, clinical chemistry, hematology, transfusion serology testing, molecular diagnostics PCR instruments, point-of-care systems, rapid lateral flow tests, and molecular point-of-care testing for pathogens such as HIV, SARS-CoV-2, influenza, RSV, and strep A. Abbott also offers pediatric and adult nutritional products including infant formula, cardiovascular devices for rhythm management and structural heart conditions, diabetes care and blood glucose monitoring products, and neuromodulation devices.
The company was founded in 1888 as Abbott Alkaloidal Company, adopted its current name in 1915, and is headquartered in Abbott Park, Illinois. As a large-cap healthcare equipment company, Abbott operates in a sector characterized by high regulatory standards and long product development cycles, with its diversification across pharmaceuticals, diagnostics, nutrition, and devices providing multiple revenue streams across both consumer and clinical end markets.
- FreeStyle Libre fuels Diabetes Care double-digit revenue growth
- Similac recall weighs on Nutritional Products segment sales
- Cardiovascular devices drive Medical Devices margin expansion
| Net Income: 5.42b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -0.08 > 1.0 |
| NWC/Revenue: 14.39% < 20% (prev 25.58%; Δ -11.20% < -1%) |
| CFO/TA 0.09 > 3% & CFO 9.90b > Net Income 5.42b |
| Net Debt (27.9b) to EBITDA (10.7b): 2.62 < 3 |
| Current Ratio: 1.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.74b) vs 12m ago -0.46% < -2% |
| Gross Margin: 56.80% > 18% (prev 52.79%; Δ 4.02% > 0.5%) |
| Asset Turnover: 48.22% > 50% (prev 51.32%; Δ -3.10% > 0%) |
| Interest Coverage Ratio: 12.45 > 6 (EBIT TTM 7.93b / Interest Expense TTM 637.0m) |
| A: 0.06 (Total Current Assets 24.5b - Total Current Liabilities 17.8b) / Total Assets 109b |
| B: 0.46 (Retained Earnings 49.8b / Total Assets 109b) |
| C: 0.08 (EBIT TTM 7.93b / Avg Total Assets 96.6b) |
| D: 0.89 (Book Value of Equity 51.1b / Total Liabilities 57.5b) |
| Altman-Z'' = 3.37 = A |
| DSRI: 1.00 (Receivables 8.60b/7.97b, Revenue 46.6b/43.1b) |
| GMI: 0.93 (GM 52.79% / 56.80%) |
| AQI: 1.15 (AQ_t 0.66 / AQ_t-1 0.57) |
| SGI: 1.08 (Revenue 46.6b / 43.1b) |
| TATA: -0.04 (NI 5.42b - CFO 9.90b) / TA 109b) |
| Beneish M = -2.95 (Cap -4..+1) = A |
As of October 09, 2026, the stock is trading at USD 98.49 with a total of 11,941,754 shares traded. Over the past week, the price has changed by +1.86%, over one month by -6.66%, over three months by +4.22% and over the past year by -24.95%.
Current recommended Stop Loss: 92.50 (which is 6.1% or 2.5 ATR below the current price).
Abbott Laboratories has received a consensus analysts rating of 4.48. Therefore, it is recommended to buy ABT.
- StrongBuy: 18
- Buy: 4
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 120.3 | 22.1% |
P/E Trailing = 31.9109
P/E Forward = 17.094
P/S = 3.5915
P/B = 3.5038
P/EG = 1.8991
Revenue TTM = 46.6b USD
EBIT TTM = 7.93b USD
EBITDA TTM = 10.7b USD
Long Term Debt = 9.90b USD (from longTermDebt, last fiscal year)
Short Term Debt = 3.00b USD (from shortTermDebt, last quarter)
Debt = 33.5b USD (from shortLongTermDebtTotal, last quarter) + Leases 931.0m
Net Debt = 27.9b USD (calculated: Debt 33.5b - CCE 5.60b)
Enterprise Value = 195b USD (167b + Debt 33.5b - CCE 5.60b)
Interest Coverage Ratio = 12.45 (Ebit TTM 7.93b / Interest Expense TTM 637.0m)
EV/FCF = 22.39x (Enterprise Value 195b / FCF TTM 8.72b)
FCF Yield = 4.47% (FCF TTM 8.72b / Enterprise Value 195b)
FCF Margin = 18.72% (FCF TTM 8.72b / Revenue TTM 46.6b)
Net Margin = 11.65% (Net Income TTM 5.42b / Revenue TTM 46.6b)
Gross Margin = 56.80% ((Revenue TTM 46.6b - Cost of Revenue TTM 20.1b) / Revenue TTM)
Gross Margin QoQ = 58.00% (prev 56.28%)
Tobins Q-Ratio = 1.79 (Enterprise Value 195b / Total Assets 109b)
Interest Expense / Debt = 1.90% (Interest Expense 637.0m / Debt 33.5b)
Taxrate = 27.77% (2.09b / 7.51b)
NOPAT = 5.73b (EBIT 7.93b * (1 - 27.77%))
Current Ratio = 1.38 (Total Current Assets 24.5b / Total Current Liabilities 17.8b)
Debt / Equity = 0.66 (Debt 33.5b / totalStockholderEquity, last quarter 51.1b)
Debt / EBITDA = 2.62 (Net Debt 27.9b / EBITDA 10.7b)
Debt / FCF = 3.20 (Net Debt 27.9b / FCF TTM 8.72b)
Total Stockholder Equity = 51.6b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.62% (Net Income 5.42b / Total Assets 109b)
RoE = 10.52% (Net Income TTM 5.42b / Total Stockholder Equity 51.6b)
RoCE = 12.91% (EBIT 7.93b / Capital Employed (Equity 51.6b + L.T.Debt 9.90b))
RoIC = 6.22% (NOPAT 5.73b / Invested Capital 92.1b)
WACC = 4.49% (E(167b)/V(201b) * Re(5.11%) + D(33.5b)/V(201b) * Rd(1.90%) * (1-Tc(0.28)))
Discount Rate = 5.11% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -62.03 | Cagr: -0.18%
[DCF] Terminal Value 77.97% ; FCFF base≈7.94b ; Y1≈9.10b ; Y5≈13.4b
[DCF] Fair Price = 100.4 (EV 202b - Net Debt 27.9b = Equity 174b / Shares 1.73b; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 98.73 | EPS CAGR: 8.24% | SUE: 2.12 | # QB: 1
Revenue Correlation: 98.45 | Revenue CAGR: 5.64% | SUE: 0.49 | # QB: 0
EPS current Quarter (2026-09-30): EPS=1.42 | Chg30d=+0.04% | Revisions=-15% | Analysts=22
EPS current Year (2026-12-31): EPS=5.52 | Chg30d=+0.01% | Revisions=+44% | GrowthEPS=+7.2% | GrowthRev=+13.3%
EPS next Year (2027-12-31): EPS=6.07 | Chg30d=+0.01% | Revisions=+12% | GrowthEPS=+9.9% | GrowthRev=+8.6%
[Analyst] Revisions Ratio: +6% (up=15, down=13)